[Clinical effects of metharmon F for postmenopausal women with climacteric symptoms: its relationship with serum level of hormones].
D015114:Androstenediol / Q000627:therapeutic use*; D000734:Androstenediols / Q000627:therapeutic use*; D000735:Androstenedione / Q000627:therapeutic use*; D002979:Climacteric / Q000187:drug effects*; D004338:Drug Combinations / Q000627:therapeutic use; D004967:Estrogens / Q000097:blood; D004970:Estrone / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D011284:Pregnenolone / Q000627:therapeutic use*; D013739:Testosterone / Q000627:therapeutic use*; D013962:Thyroid (USP) / Q000627:therapeutic use*; D013963:Thyroid Hormones / Q000627:therapeutic use*
D000734:Androstenediols; D004338:Drug Combinations; D004967:Estrogens; D013962:Thyroid (USP); D013963:Thyroid Hormones; D004970:Estrone; D013739:Testosterone; D000735:Androstenedione; D011284:Pregnenolone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C039452:Metharmon F; D015114:Androstenediol